A humanized bispecific killer cell engager (BiKE) antibody containing binding sites for CD16 and CD33 (CD16x33 BiKE) has been shown to trigger NK cell activation in preclinical studies and could potentially enhance and direct the GVL effect in patients with CD33+ AML after transplant, especially after CMV reactivation [72]. This evidence concerns the gene CD33 and acute myeloid leukemia.